Eli Lilly on Tuesday announced plans to acquire three companies for almost $4 billion in cash, as it looks to expand its research and development business into infectious diseases.
The company said it had agreed deals to buy Curevo, LimmaTech Biologics and Vaccine Company for $1.5 billion, $780 million and $1.55 billion, respectively.
Shares of Eli Lilly rose 1.3% in premarket trading on the news.
“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Daniel M. Skovronsky, chief scientific and product officer and president, said in a statement.
This is breaking news story, please refresh for updates.
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals NYT News Today.
Hence then, the article about eli lilly stock edges higher as company plans nearly 4 billion in vaccine deals was published today ( ) and is available on NY Times News ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals )
Also on site :
- Decorated local aviator details his pursuit of recognition for his fellow shadow warriors of the Cold War
- Karol G Stunned by Surprise AMAs Win After Accepting International Artist of Excellence: ‘My Life Is Meaningful Because of My Music’
- Katseye Brings the AMAs’ House Down With Beary Exciting ‘Pinky Up’ Performance, Before Winning Best New Artist